Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis

BMB Reports

Volumn 41, Issue 4, 2008, Pages 278-286

  Shibuya, Masabumi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Anti angiogenic therapy; Dll4; Tumor angiogenesis; VEGF; VEGF receptor

Indexed keywords

VERTEBRATA;

EID: 43249114710     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2008.41.4.278     Document Type: Short Survey

References (75)

1. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
2. Ferrara, N. and Davis-Smyth, T. (1997) The biology of vascular endothelial growth factor. Endocrine Rev. 18, 4-25.
3. Shibuya, M. and Claesson-Welsh, L. (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell. Res. 312, 549-560.
4. Dvorak, HF. (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380.
5. Takahashi, H. and Shibuya, M. (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond). 109, 227-241.
6. Carmellet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kleckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawlling, J., Moons, L., Collen, D., Risau, W. and Nagy, A. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
7. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, KS., Powell-Braxton, L., Hillan, KJ. and Moore, MW. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380,439-442.
8. Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C. and Shima, DT.(2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16, 2684-2698.
9. Maes, C., Carmeliet, P., Moermans, K., Stockmans, I., Smets, N., Collen, D., Bouillon, R. and Carmeliet, G.(2002) Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech. Dev. 111,61-73.
10. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, JM., Lane, WS. and Kaelin, WG Jr. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468.
11. Jaakkola, P., Mole, DR., Tian, YM., Wilson, MI., Gielbert, J., Gaskell, SJ., Kriegsheim, Av., Hebestreit, HF., Mukherji, M., Schofield, CJ., Maxwell, PH., Pugh, CW. and Ratcliffe, PJ.(2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472.
12. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., DiPalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., Vandendriessche, T., Ponten, A., Eriksson, U., Plate, KH., Foidart, JM., Schaper, W., Charnock-Jones, DS., Hicklin, DJ., Herbert, JM., Collen, D. and Persico, MG. (2001)Synergism between vascular endothelial growth factor andplacental growth factor contributes to angiogenesis andplasma extravasation in pathological conditions. Nat. Med.7, 575-583.
13. Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M. and Shibuya, M.(2002) MMP9 induction by Vascular Endothelial Growth Factor Receptor-1 is involved in lung specific metastasis. Cancer Cell 2, 289-300.
14. Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, JA., Hooper, A., Priller, J., De Klerck, B., Compernolle, V., Daci, E., Bohlen, P., Dewerchin, M., Herbert, JM., Fava, R., Matthys, P., Carmeliet, G., Collen, D., Dvorak, HF., Hicklin, DJ. and Carmeliet P. (2002)Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831-840.
15. Murakami, M., Zheng, Y., Hirashima, M., Suda, T., Morita, Y., Ooehara, J., Ema, H., Fong, GH. and Shibuya, M. (2008) VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler. Thromb. Vasc. Biol. in press.
16. McColl, BK., Paavonen, K., Karnezis, T., Harris, NC., Davydova, N., Rothacker, J., Nice, EC., Harder, KW., Roufail, S., Hibbs, ML., Rogers, PA., Alitalo, K., Stacker, SA. and Achen, MG. (2007) Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J. 21, 1088-1098.
17. Lyttle, DJ., Fraser, KM., Fleming, SB., Mercer, AA. And Robinson, AJ. (1994) Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68, 84-92.
18. Meyer, M., Clauss, M., Lepple-Wienhues, A., Waltenberger, J., Augustin, HG., Ziche, M., Lanz, C., Buttner, M., Rziha, HJ. and Dehio, C. (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but notVEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18,363-374.
19. Ogawa, S., Oku, A., Sawano, A., Yamaguchi, S., Yazaki, Y. and Shibuya, M. (1998) A novel type of Vascular Endothelial Growth Factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273, 31273-31282.
20. Wise, LM., Veikkola, T., Mercer, AA., Savory, LJ., Fleming, SB., Caesar, C., Vitali, A., Makinen, T., Alitalo, K. and Stacker, SA. (1999) Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. U.S.A. 96, 3071-3076.
21. Kiba, A., Sagara, H., Hara, T. and Shibuya, M. (2003a) VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem. Biophys. Res. Commun. 301, 371-377.
22. Kunstfeld, R., Hirakawa, S., Hong, YK., Schacht, V., Lange-Asschenfeldt, B., Velasco, P., Lin, C., Fiebiger, E., Wei, X., Wu, Y., Hicklin, D., Bohlen, P. and Detmar, M. (2004) Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104, 1048-1057.
23. Larcher, F., Murillas, R., Bolontrade, M., Conti, CJ. and Jorcano, JL. (1998) VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17, 303-311.
24. Zheng, Y., Murakami, M., Takahashi, H., Yamauchi, M., Kiba, A., Yamaguchi, S., Yabana, N., Alitalo, K. and Shibuya, M. (2006) Chimeric VEGF-ENZ7/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler. Thromb. Vasc. Biol. 26, 2019-2026.
25. Inoue, N., Kondo, T., Kobayashi, K., Aoki, M., Numaguchi, Y., Shibuya, M. and Murohara, T. (2007) Therapeutic angiogenesis using novel Vascular Endothelial Growth Factor-E/ human Placental Growth Factor chimera genes. Arterioscler. Thromb. Vasc. Biol. 27, 99-105.
26. Kiba, A., Yabana, N. and Shibuya, M. (2003b) A set of loop-1 and -3 structures in the novel VEGF family member, VEGF-ENZ-7, is essential for the activation of VEGFR-2 signaling. J. Biol. Chem. 278, 13453-13461.
27. Zheng, Y., Watanabe, M., Kuraishi, T., Hattori, S., Kai, C. and Shibuya, M. (2007) Chimeric VEGF-ENZ7/PlGF specifically binding to VEGFR-2 accelerates skin wound healing via enhancement of neovascularization. Arterioscler. Thromb. Vasc. Biol. 27, 503-511.
28. Takahashi, H., Hattori, S., Iwamatsu, A., Takizawa, H. and Shibuya, M. (2004) A novel snake venom Vascular Endothelial Growth Factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF Receptor-1. J. Biol. Chem. 279, 46304-46314.
29. Matthews, W., Jordan, CT., Gavin, M., Jenkins, NA., Copeland, NG. and Lemischka, IR. (1991) A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. U.S.A. 88, 9026-9030.
30. Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H. and Sato, M. (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5, 519-524.
31. Shibuya, M. (1995) Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 67,281-316.
32. Terman, BI., Carrion, ME., Kovacs, E., Rasmussen, BA., Eddy, R. and Shows, TB. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677-1683.
33. Alitalo, K. and Carmeliet, P. (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227.
34. Veikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, TV., Kubo, H., Thurston, G., McDonald, DM., Achen, MG., Stacker, SA. and Alitalo, K. (2001) Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, 1223-1231.
35. Barleon, B., Sozzani, S., Zhou, D., Weich, H. A., Martovani, A. and Marme, D. (1996) Migration of human monocytes in response to Vascular Endothelilal Growth Factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336-3343.
36. Clauss, M., Weich, H., Breier, G., Knies, U., Rockl, W., Waltenberger, J. and Risau, W. (1996) The Vascular Endothelial Growth Factor Receptor Flt-1 madiates biological activities. J. Biol. Chem. 271, 17629-17634.
37. Sawano, A., Iwai, S., Sakurai, Y., Ito, M., Shitara, K, Nakahata, T. and Shibuya, M. (2001) Vascular Endothelial Growth Factor Receptor-1 (Flt-1) is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97, 785-791.
38. Lin, EY., Li, JF., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, DA., Qian, H., Xue, XN. and Pollard, JW. (2006)Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246.
39. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, NR., Crystal, RG., Moore, MA., Hajjar, KA., Manova, K., Benezra, R., andRafii, S. (2001) Impaired recruitment of bone-marrow-derivedendothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201.
40. Murakami, M., Iwai, S., Hiratsuka, S., Yamauchi, M., Nakamura, K., Iwakura, Y. and Shibuya, M. (2006) Signaling of vascular endothelial growth factor receptor-1tyrosine kinase promotes rheumatoid arthritis through activation of monocyte/macrophages. Blood 108, 1849-1856.
41. Fong, GH., Rossant, J., Gertsentein, M. and Breitman, ML. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376,66-70.
42. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. and Shibuya, M. (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 95, 9349-9354.
43. Kaplan, RN., Riba, RD., Zacharoulis, S., Bramley, AH., Vincent, L., Costa, C., MacDonald, DD., Jin, DK., Shido, K., Kerns, SA., Zhu, Z., Hicklin, D., Wu, Y., Port, JL., Altorki, N., Port, ER., Ruggero, D., Shmelkov, SV., Jensen, KK., Rafii, S. and Lyden, D. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438, 820-827.
44. Kendall, RL. and Thomas, KA. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 10705-10709.
45. Yamaguchi, S., Iwata, K. and Shibuya, M. (2002) Soluble Flt-1 (soluble VEGFR-1), a potent natural anti-angiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem. Biophys. Res. Commun. 291, 554-559.
46. Koga, K., Osuga, Y., Yoshino, O., Hirota, Y., Ruimeng, X., Hirata, T., Takeda, S., Yano, T., Tsutsumi, O. and Taketani, Y. (2003) Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88, 2348-2351.
47. Levine, RJ., Maynard, SE., Qian, C., Lim, KH., England, LJ., Yu, KF., Schisterman, EF., Thadhani, R., Sachs, BP., Epstein, FH., Sibai, BM., Sukhatme, VP. and Karumanchi, SA. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683.
48. Maynard, SE., Min, JY., Merchan, J., Lim, KH., Li, J., Mondal, S., Libermann, TA., Morgan, JP., Sellke, FW., Stillman, IE., Epstein, FH., Sukhatme, VP. and Karumanchi, SA. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658.
49. Das, B., Yeger, H., Tsuchida, R., Torkin, R., Gee, MF., Thorner, PS., Shibuya, M., Malkin, D. and Baruchel, S. (2005) A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res. 65, 7267-7275.
50. Tsuchida, R., Das, B., Yeger, H., Koren, G., Shibuya, M., Thorner, PS., Baruchel, S. and Malkin, D. (2008) Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene in press.
51. Shalaby, F., Rossant, J., Yamaguchi, TP., Gertsenstein, M., Wu, XF., Breitman, ML. and Schuh, AC. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
52. Takahashi, T., Ueno, H. and Shibuya, M. (1999) VEGF activates Protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221-2230.
53. Xia, P., Aiello, LP., Ishii, H., Jiang, ZY., Park, DJ., Robinson, GS., Takagi, H., Newsome, WP., Jirousek, MR. and King, GL. (1996) Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98, 2018-2026.
54. Takahashi, T., Yamaguchi, S., Chida, K. and Shibuya, M. (2001) A Single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768-2778.
55. Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. and Shibuya, M. (2005). Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 102, 1076-1081.
56. Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, JH,, Wernstedt, C., Wu, J., Bruheim, S., Mugishima, H., Mukhopadhyay, D., Spurkland, A. and Claesson-Welsh L. (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 24, 2342-2353.
57. Soker, S., Takashima, S., Miao, HQ., Neufeld, G. and Klagsbrun, M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745.
58. Kopfstein, L., Veikkola, T., Djonov, VG., Baeriswyl, V., Schomber, T., Strittmatter, K., Stacker, SA., Achen, MG., Alitalo, K. and Christofori, G. (2007) Distinct roles of vascularendothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol. 170, 1348-1361.
59. Mäkinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E.C., Wise, L., Mercer, A., Kowalski, H., Kerjaschki, D., Stacker, S.A., Achen, M.G., and Alitalo, K. (2001) Isolated lymphatic endothelial cells transducer growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20, 4762-4773.
60. Luo, JC., Yamaguchi, S., Shinkai, A., Shitara, K. and Shibuya, M. (1998) Significant expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor in mouse ascites tumors. Cancer Res. 58, 2652-2660.
61. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S. and Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
62. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross R. and Kabbinavar, F. (2004) Bevacizumab plusirinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
63. Sandler, A., Gray, R., Perry, MC., Brahmer, J., Schiller, JH., Dowlati, A., Lilenbaum, R. and Johnson, DH. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550.
64. Cohen, MH., Gootenberg, J., Keegan, P. and Pazdur, R. (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12, 713-718.
65. Lee, S., Chen, TT., Barber, CL., Jordan, MC., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, KP. and Iruela-Arispe, ML. (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703.
66. Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., Autiero, M., Wyns, S., Plaisance, S., Moons, L., van Rooijen, N., Giacca, M., Stassen, JM., Dewerchin, M., Collen, D. and Carmeliet, P.(2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475.
67. Cho, CH., Kim, KE., Byun, J., Jang, HS., Kim, DK., Baluk, P., Baffert, F., Lee, GM., Mochizuki, N., Kim, J., Jeon, BH., McDonald, DM. and Koh, GY. (2005) Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ. Res. 97, 86-94.
68. Uemura, A., Ogawa, M., Hirashima, M., Fujiwara, T., Koyama, S., Takagi, H., Honda, Y., Wiegand, SJ., Yancopoulos, GD. and Nishikawa, S. (2002) Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J. Clin. Invest. 110, 1619-1628.
69. Wang, HU., Chen, ZF. and Anderson, DJ. (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741-753.
70. Gale, NW., Dominguez, MG., Noguera, I., Pan, L., Hughes, V., Valenzuela, DM., Murphy, AJ., Adams, NC., Lin, HC., Holash, J., Thurston, G. and Yancopoulos, GD. (2004) Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl. Acad. Sci. U.S.A. 101, 15949-15954.
71. Noguera-Troise, I., Daly, C., Papadopoulos, NJ., Coetzee, S., Boland, P., Gale, NW., Lin, HC., Yancopoulos, GD. and Thurston, G. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032-1037.
72. Saito, M., Hamasaki, M. and Shibuya, M. (2003) Tubular formation by Angiopoietin-1 in endothelial cell/fibroblast co-culture is dependent on endogenous VEGF. Cancer Sci. 94, 782-790.
73. Yamauchi, M., Imajoh-Ohmi, S. and Shibuya, M. (2007) A novel anti-angiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci. 98, 1491-1497.
74. Kiyono, M. and Shibuya, M. (2003) Bone morphogenetic protein 4 mediates apoptosis of capillary endothelial cells during rat pupillary membrane regression. Mol. Cell. Biol. 23, 4627-4636.
75. Kiyono, M. and Shibuya, M. (2006) Inhibitory Smad transcription factors protect arterial endothelial endothelial cells from apoptosis induced by BMP4. Oncogene 25, 7131-7137.